Ken Griffin Astrazeneca PLC Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$63.2 - $79.58 $88.4 Million - $111 Million	1,398,300 Added 108.04%	2,692,600 $176 Million
Q3 2024 Nov 14, 2024	SELL	$76.67 - $87.62 $70.7 Million - $80.8 Million	-922,100 Reduced 41.6%	1,294,300 $101 Million
Q2 2024 Aug 14, 2024	BUY	$66.81 - $80.83 $30.9 Million - $37.3 Million	461,800 Added 26.32%	2,216,400 $173 Million
Q1 2024 May 15, 2024	BUY	$61.03 - $69.57 $34.4 Million - $39.2 Million	563,100 Added 47.26%	1,754,600 $119 Million
Q4 2023 Feb 14, 2024	SELL	$61.89 - $69.28 $32.6 Million - $36.5 Million	-527,400 Reduced 30.68%	1,191,500 $80.2 Million
Q3 2023 Nov 14, 2023	BUY	$64.85 - $71.7 $62.7 Million - $69.3 Million	967,000 Added 128.61%	1,718,900 $116 Million
Q2 2023 Aug 14, 2023	BUY	$69.91 - $75.81 $14.7 Million - $15.9 Million	210,000 Added 38.75%	751,900 $53.8 Million
Q1 2023 May 15, 2023	SELL	$63.15 - $71.6 $13.3 Million - $15.1 Million	-210,432 Reduced 27.97%	541,900 $37.6 Million
Q4 2022 Feb 14, 2023	BUY	$54.21 - $70.44 $19.1 Million - $24.8 Million	351,736 Added 87.8%	752,332 $51 Million
Q3 2022 Nov 14, 2022	SELL	$53.02 - $135.75 $5.98 Million - $15.3 Million	-112,712 Reduced 21.96%	400,596 $22 Million

1,353

512M

6.08M

4.44M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $232B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.